• Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

      Braun, Hannan M.; Candelario, Jury; Hanlon, Courtney L.; Segura, Eddy R.; Clark, Jesse L.; Currier, Judith S.; Lake, Jordan E.; School of Medicine, University of California, San Francisco, San Francisco, California.; APAIT, Special Service for Groups, Los Angeles, California.; Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.; South American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.; South American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.; South American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.; South American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.; Jordan.E.Lake@uth.tmc.edu (Mary Ann Liebert Inc., 2017-10)
      Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.